MedTrace Logo

Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer

NCT07579286 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-12

No results posted yet for this study

Summary

Sentinel lymph node biopsy (SLNB) is the standard of axillary lymph node surgical staging in patients with early breast cancer.

The main goal of the study is to abandon axillary surgery in patients over 59 years old with early, luminal A, clinical lymph node negative breast cancer.

Conditions

  • Early Breast Cancer

Interventions

PROCEDURE

breast resection

breast resection without sentinel lymph node biopsy, radiotherapy to the breast area and sentinel lymph nodes

PROCEDURE

Breast resection with sentinel lymph node biopsy

Breast resection with sentinel lymph node biopsy, radiotherapy to the breast and axilla according to current treatment standards

Sponsors & Collaborators

  • N.N. Petrov National Medical Research Center of Oncology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-27
Primary Completion
2027-05-25
Completion
2027-05-25

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07579286 on ClinicalTrials.gov